To provide the information your oncologist is not telling you or doesn't have the time to!
Unleash the power of your body’s immune system in the fight against cancer with our “Immunotherapy” subcategory. Delve into the realm of groundbreaking treatments that empower your immune system to recognize and combat cancer cells. Explore the latest advances in immunotherapy, from checkpoint inhibitors to CAR-T cell therapies, and learn how they are revolutionizing the landscape of cancer treatment. Join us on a journey to understand how harnessing your body’s natural defenses is paving the way for more targeted and effective therapies in the fight against cancer.
This is a new modified TIL protocol developed by Obsidian Therapeutics now open for enrollment at the Orlando Health Cancer Institute. All information provided here are from public sources and the protocol details can be found here. Please reach out to Karin Donaldson if interest in seeking this trial. This current protocol is specific for …
This post is based on the interesting results published by Routy et al. Nature July 2023. I am hoping that we will soon open a protocol using FMT in cancer patients and I will announce once we’re site activated at the Orlando Health Cancer Institute. The revolutionary world of cancer treatment is once again on …
Intratumoral therapies is another class of immunotherapeutics that I often consider especially for folks with limited skin or nodal disease or perhaps deeper oligometastatic disease. I have cutaneous malignancies patients with Melanoma, Cutaneous SCC, Merkel cell and Kaposi sarcomas that have responded to local intratumoral therapies. We’ve seen viral agents like FDA approved TVEC, RP1, …
Here’s an interested case of a patient with MCC that I saw this past week. While I’d like to consider systemic immunotherapy with PD1 or dual checkpoint inhibitors, chemotherapy, clinical trial with MDNA or TLR9 agonist/PD1, this patient’s disease was limited to the skin alone. Could we do something different and perhaps with less risk …
Great review article published in the JCO here by Daniel Olson et al. summarizing adoptive cellular therapy for solid tumors and where we are today. I am very excited about solid tumor cellular therapy as we are currently enrolling into solid tumor trials specifically for TIL, PD1 knockout TIL, Neoantigen Selective TIL and TCR MAGE4+ …
Replaying this post as a reminder that this study is enrolling at multiple sites globally. More detailed information can also be seen here at clinicaltrials.gov as well as the sponsor Iovance. All information and data stated in this article are available publicly through online resources that I’ve also linked below for reference. This new trial …
mRNA technology has revolutionized the world of medicine. Known for its role in the creation of COVID-19 vaccines, mRNA has been lauded as a game-changer in the fight against infectious diseases. But mRNA’s impact extends far beyond pandemic control. It’s now making waves in another critical area of healthcare: cancer treatment and prevention. mRNA stands …
I am really excited about this new protocol specifically for patients with MAGE4+ HLA restricted SPEAR TILs for Metastatic Melanoma, Non-small Cell Lung Cancer, Head Neck cancer, Ovarian, Endometrial, and Urothelial cancers. The Gastric and Esophageal Cancer cohorts are closed. The social media material seen here was approved both the sponsor and IRB. Please contact …
Melanoma is a tricky disease that often comes back when you least expect it. Just like a sneaky burglar who breaks into your house when you’re not looking, melanoma can hide in your body and then suddenly reappear. That’s exactly what happened to one of my patients, who thought she had beaten the disease years …
I have sponsor, regulatory and IRB permissions/approval to post this blog publicly on social media. I am very excited about this protocol using TILs for breast cancer, colorectal, uveal melanomas, and now also inclusive of cutaneous melanoma, nsclc, head/neck carcinoma. Further details can be found here at the sponsor site and at clinical trials.gov. Adoptive …